Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
45 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Rubella - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Rubella - Pipeline Review, H2 2014', provides an overview of the Rubella's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Rubella, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rubella and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Rubella - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rubella and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rubella products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Rubella pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Rubella - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Rubella pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Rubella Overview 6 Therapeutics Development 7 Pipeline Products for Rubella - Overview 7 Pipeline Products for Rubella - Comparative Analysis 8 Rubella - Therapeutics under Development by Companies 9 Rubella - Therapeutics under Investigation by Universities/Institutes 11 Rubella - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Unknown Stage Products 15 Rubella - Products under Development by Companies 16 Rubella - Products under Investigation by Universities/Institutes 17 Rubella - Companies Involved in Therapeutics Development 18 Beijing Tiantan Biological Products Co., Ltd. 18 Biological E. Limited 19 China National Pharmaceutical Group Corporation 20 GlaxoSmithKline plc 21 Prometheon Pharma, LLC 22 Sinovac Biotech Ltd. 23 Universal Stabilization Technologies, Inc. 24 Zydus Cadila Healthcare Limited 25 Rubella - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Combination Products 27 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 Cell Therapy for Measles, Mumps and Rubella - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 measles + mumps + rubella + varicella vaccine - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 measles + mumps + rubella + varicella vaccine - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 measles + mumps + rubella vaccine - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 measles + mumps + rubella vaccine - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 measles + mumps + rubella vaccine - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 measles + rubella vaccine - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 measles + rubella vaccine - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 measles + rubella vaccine - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 rubella vaccine - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Rubella - Recent Pipeline Updates 42 Rubella - Dormant Projects 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 45 Disclaimer 45
List of Tables Number of Products under Development for Rubella, H2 2014 7 Number of Products under Development for Rubella - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 10 Number of Products under Investigation by Universities/Institutes, H2 2014 11 Comparative Analysis by Late Stage Development, H2 2014 12 Comparative Analysis by Clinical Stage Development, H2 2014 13 Comparative Analysis by Early Stage Development, H2 2014 14 Comparative Analysis by Unknown Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Products under Investigation by Universities/Institutes, H2 2014 17 Rubella - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2014 18 Rubella - Pipeline by Biological E. Limited, H2 2014 19 Rubella - Pipeline by China National Pharmaceutical Group Corporation, H2 2014 20 Rubella - Pipeline by GlaxoSmithKline plc, H2 2014 21 Rubella - Pipeline by Prometheon Pharma, LLC, H2 2014 22 Rubella - Pipeline by Sinovac Biotech Ltd., H2 2014 23 Rubella - Pipeline by Universal Stabilization Technologies, Inc., H2 2014 24 Rubella - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 25 Assessment by Monotherapy Products, H2 2014 26 Assessment by Combination Products, H2 2014 27 Number of Products by Stage and Route of Administration, H2 2014 29 Number of Products by Stage and Molecule Type, H2 2014 31 Rubella Therapeutics - Recent Pipeline Updates, H2 2014 42 Rubella - Dormant Projects, H2 2014 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.